PLRX vs. SAVA, TYRA, ARCT, PRAX, MGNX, ARQT, EOLS, TNGX, ORIC, and PRTC
Should you be buying Pliant Therapeutics stock or one of its competitors? The main competitors of Pliant Therapeutics include Cassava Sciences (SAVA), Tyra Biosciences (TYRA), Arcturus Therapeutics (ARCT), Praxis Precision Medicines (PRAX), MacroGenics (MGNX), Arcutis Biotherapeutics (ARQT), Evolus (EOLS), Tango Therapeutics (TNGX), ORIC Pharmaceuticals (ORIC), and PureTech Health (PRTC). These companies are all part of the "pharmaceutical preparations" industry.
Cassava Sciences (NASDAQ:SAVA) and Pliant Therapeutics (NASDAQ:PLRX) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their media sentiment, earnings, dividends, community ranking, profitability, institutional ownership, risk, analyst recommendations and valuation.
Cassava Sciences received 37 more outperform votes than Pliant Therapeutics when rated by MarketBeat users. However, 68.67% of users gave Pliant Therapeutics an outperform vote while only 66.20% of users gave Cassava Sciences an outperform vote.
Cassava Sciences presently has a consensus target price of $124.00, suggesting a potential upside of 511.14%. Pliant Therapeutics has a consensus target price of $48.44, suggesting a potential upside of 225.13%. Given Pliant Therapeutics' higher probable upside, research analysts plainly believe Cassava Sciences is more favorable than Pliant Therapeutics.
Cassava Sciences has a net margin of 0.00% compared to Cassava Sciences' net margin of -2,872.79%. Cassava Sciences' return on equity of -31.15% beat Pliant Therapeutics' return on equity.
In the previous week, Cassava Sciences had 12 more articles in the media than Pliant Therapeutics. MarketBeat recorded 15 mentions for Cassava Sciences and 3 mentions for Pliant Therapeutics. Cassava Sciences' average media sentiment score of 0.83 beat Pliant Therapeutics' score of 0.27 indicating that Pliant Therapeutics is being referred to more favorably in the news media.
Cassava Sciences has higher earnings, but lower revenue than Pliant Therapeutics. Cassava Sciences is trading at a lower price-to-earnings ratio than Pliant Therapeutics, indicating that it is currently the more affordable of the two stocks.
Cassava Sciences has a beta of -0.42, meaning that its share price is 142% less volatile than the S&P 500. Comparatively, Pliant Therapeutics has a beta of 1.13, meaning that its share price is 13% more volatile than the S&P 500.
38.1% of Cassava Sciences shares are owned by institutional investors. Comparatively, 97.3% of Pliant Therapeutics shares are owned by institutional investors. 9.0% of Cassava Sciences shares are owned by insiders. Comparatively, 5.6% of Pliant Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Summary
Pliant Therapeutics beats Cassava Sciences on 9 of the 16 factors compared between the two stocks.
Get Pliant Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for PLRX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding PLRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartThis chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Pliant Therapeutics Competitors List
Related Companies and Tools